In the past 52 weeks, Spectrum Pharmaceuticals share prices have been bracketed by a low of $5.51 and a high of $15.09 and are now at $13.73, 149% above that low price. Over the last five market days, the 200-day moving average (MA) has gone up 1.1% while the 50-day MA has advanced 3.5%.
Spectrum Pharmaceuticals Inc. develops in-licensed drugs for the treatment and supportive care of cancer patients. The Company's satraplatin is an oral, anti-cancer drug. Spectrum's Elsamitrucin targets non-Hodgkin's lymphoma, and Neoquin is being studied in the treatment of superficial bladder cancer. Spectrum also has a pipeline of pre-clinical neurological drug candidates.
SmarTrend will continue to scan these moving averages and a number of other proprietary indicators for any shifts in the trajectory of Spectrum Pharmaceuticals shares.Log in and add Spectrum Pharmaceuticals (SPPI) to your watchlist today so you can receive a real-time alert when the shares are about to change trendFor the latest updates on the stock market, visit Stock Market Today For the latest updates PRESS CTR + D or visit Stock Market news Today
No comments:
Post a Comment